You are here: Industry Insights > BI

News List

FDA fast-tracks BI, Lilly's Jardiance in chronic heart failure fiercepharma
June 28, 2019
When Boehringer Ingelheim and Eli Lilly’s diabetes med Jardiance first showed CV benefits in trial patients, it changed the game for the SGLT2 inhibitor class.
BI, Lilly announces results of new post-hoc analysis of data from the EMPA-REG OUTCOME trial biospectrumasia
June 18, 2019
In this new post-hoc analysis, the effect of empagliflozin on reducing the risk of cardiovascular and kidney outcomes was consistent between people in the EMPA-REG OUTCOME trial who had chronic kidney disease without overt proteinuria and all others in th
Boehringer Ingelheim axes biosimilars development outside US pharmaphorum
December 06, 2018
Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible.
BI partners with Tsinghua for immuno therapies biospectrumasia
September 06, 2018
This collaboration is an initiative of Boehringer Ingelheim’s Research Beyond Borders (RBB) and Cancer Immunology and Immune Modulation Research Departments.
BI snaps up OSE’s novel checkpoint inhibitor pharmatimes
July 18, 2018
Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.
BI, Dicerna to develop RNAi therapeutics for liver disease pharmatimes
November 06, 2017
Boehringer Ingelheim has linked with US group Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases.